Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ:ANTX)

1.090 +0.040 (+3.81%)
Streaming Delayed Price Updated: 1:21 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AN2 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics to Participate at Upcoming Investor Conferences
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
Citizens And 2 Other Penny Stocks Insiders Are Buying ↗
 
Via Benzinga
News headline image
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024 ↗
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
News headline image
Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results ↗
 
Via Benzinga
News headline image
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.